Durvalumab
Imfinzi (durvalumab) is an antibody pharmaceutical. Durvalumab was first approved as Imfinzi on 2017-05-01. It is used to treat transitional cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against programmed cell death 1 ligand 1.
| Trade Name | Imfinzi |
|---|---|
| Common Name | Durvalumab |
| Indication | non-small-cell lung carcinoma, transitional cell carcinoma |
| Drug Class | Monoclonal antibodies: fully human, immunomodulating |
